CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 

X4 Pharmaceuticals Inc's Working Capital Ratio

XFOR's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2024, Working Capital Ratio deteriorated to 3.9 below X4 Pharmaceuticals Inc's average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry 52 other companies have achieved higher Working Capital Ratio than X4 Pharmaceuticals Inc in first quarter 2024. While Working Capital Ratio total ranking in the first quarter 2024 has deteriorated compared to the prior quarter from 506 to 769.

Explain Working Capital Ratio
How much in Current Assets XFOR´s has?
What is the value of XFOR´s Current Liabilities?


XFOR Working Capital Ratio (Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change 6.07 % -11.74 % 1.14 % 32.08 % 63.16 %
Y / Y Current Assets Change -32.13 % 72.51 % 180.78 % 38.57 % 46.43 %
Working Capital Ratio MRQ 3.9 6.08 7 5.36 6.09
XFOR's Total Ranking # 769 # 506 # 619 # 971 #
Seq. Current Liabilities Change -7.85 % 15.23 % 15.27 % -13.34 % -23.31 %
Seq. Current Assets Change -40.94 % 0.15 % 50.32 % -23.67 % 50.12 %



Working Capital Ratio first quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 53
Healthcare Sector # 287
Overall Market # 769


Working Capital Ratio Statistics
High Average Low
17.34 7.31 1.59
(Mar 31 2020)   (Mar 31 2019)




Financial Statements
X4 Pharmaceuticals Inc's Current Liabilities $ 22 Millions Visit XFOR's Balance sheet
X4 Pharmaceuticals Inc's Current Assets $ 87 Millions Visit XFOR's Balance sheet
Source of XFOR's Sales Visit XFOR's Sales by Geography


Cumulative X4 Pharmaceuticals Inc's Working Capital Ratio

XFOR's Working Capital Ratio for the trailling 12 Months

XFOR Working Capital Ratio

(Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth 6.07 % -11.74 % 1.14 % 32.08 % 63.16 %
Y / Y Current Assets TTM Growth -32.13 % 72.51 % 180.78 % 38.57 % 46.43 %
Working Capital Ratio TTM 5.59 6.16 5.23 4.16 4.05
Total Ranking TTM # 2591 # 3646 # 3374 # 698 #
Seq. Current Liabilities TTM Growth -7.85 % 15.23 % 15.27 % -13.34 % -23.31 %
Seq. Current Assets TTM Growth -40.94 % 0.15 % 50.32 % -23.67 % 50.12 %


  News about X4 Pharmaceuticals Inc Working Capital Ratio

X4 Pharmaceuticals Announces $125 Million Capital Infusion to Extend Cash Runway, Driving Growth and Innovation in Biopharmaceuticals Industry

X4 Pharmaceuticals Secures $125 Million Non-Dilutive Capital to Extend Cash Runway into Late 2025
X4 Pharmaceuticals Inc. recently announced a major capital infusion of $125 million, which includes $105 million from the sale of a Priority Review Voucher and a $20 million drawdown from an existing loan facility. This infusion of non-dilutive capital will extend the company's projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI (mavorixafor).
Despite a sequential decrease in current liabilities during the first quarter of 2024, X4 Pharmaceuticals Inc's working capital ratio deteriorated to 3.9, falling below the company's average of 7.46. When compared to 61 other companies within the industry, X4 Pharmaceuticals Inc ranked lower in terms of working capital ratio in the first quarter of 2024. However, the company has shown improvement, with a ranking of 619 compared to 6.08 in the third quarter of 2023.


On the trailing twelve months basis Due to decrease in Current Liabilities in the I Quarter 2024 to $22.41 millions, cumulative Working Capital Ratio decreased to 5.59 below the average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 82 other companies have achieved higher Working Capital Ratio than X4 Pharmaceuticals Inc. While Working Capital Ratio overall ranking has improved so far to 2591, from total ranking during the twelve months ending third quarter 2023 at 3646.

Explain Working Capital Ratio
How much in Current Assets XFOR´s has?
What is the value of XFOR´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 83
Healthcare Sector # 617
Within the Market # 2591


trailing twelve months Working Capital Ratio Statistics
High Average Low
12.08 6.6 3.73
(Jun 30 2020)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Working Capital RatioMar 31 2024 MRQ Current AssetsMar 31 2024 MRQ Current Liabilities
Caribou Biosciences Inc   10.49 $ 304.514  Millions$ 29.021  Millions
Entera Bio Ltd   10.07 $ 9.751  Millions$ 0.968  Millions
Adverum Biotechnologies Inc   9.24 $ 199.130  Millions$ 21.549  Millions
Prime Medicine Inc   8.91 $ 217.654  Millions$ 24.441  Millions
Passage Bio Inc   8.43 $ 108.293  Millions$ 12.841  Millions
Humacyte Inc   8.37 $ 117.926  Millions$ 14.087  Millions
Scholar Rock Holding Corp  8.26 $ 246.933  Millions$ 29.887  Millions
Tarsus Pharmaceuticals Inc   8.01 $ 340.724  Millions$ 42.528  Millions
Black Diamond Therapeutics Inc   7.05 $ 118.806  Millions$ 16.854  Millions
Fennec Pharmaceuticals Inc   6.93 $ 68.171  Millions$ 9.836  Millions
Springworks Therapeutics Inc   6.85 $ 471.798  Millions$ 68.917  Millions
Ginkgo Bioworks Holdings Inc   6.67 $ 903.020  Millions$ 135.431  Millions
Halozyme Therapeutics Inc   6.64 $ 873.584  Millions$ 131.639  Millions
Cardiff Oncology inc   6.28 $ 69.990  Millions$ 11.147  Millions
Zura Bio Limited  6.17 $ 90.474  Millions$ 14.674  Millions
Pluri Inc   6.05 $ 27.367  Millions$ 4.526  Millions
Immunocore Holdings Plc  6.01 $ 926.038  Millions$ 154.050  Millions
Senti Biosciences Inc   5.79 $ 55.666  Millions$ 9.609  Millions
Dyadic International Inc  5.54 $ 12.541  Millions$ 2.262  Millions
Twist Bioscience Corporation  5.51 $ 371.869  Millions$ 67.490  Millions
Adma Biologics Inc   5.43 $ 276.419  Millions$ 50.877  Millions
Iovance Biotherapeutics inc   5.34 $ 385.533  Millions$ 72.136  Millions
Vericel Corporation  5.20 $ 189.718  Millions$ 36.470  Millions
C4 Therapeutics Inc   5.08 $ 279.592  Millions$ 55.018  Millions
Recursion Pharmaceuticals Inc   4.65 $ 343.615  Millions$ 73.920  Millions
Curis Inc   4.63 $ 46.066  Millions$ 9.954  Millions
Editas Medicine Inc   4.60 $ 305.555  Millions$ 66.487  Millions
Dbv Technologies S a   4.51 $ 119.562  Millions$ 26.483  Millions
Intensity Therapeutics Inc   4.48 $ 11.169  Millions$ 2.493  Millions
Biomx Inc   4.40 $ 47.101  Millions$ 10.707  Millions

Date modified: 2024-05-08T15:34:55+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com